Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Naveen Ravindranathan, MD, Giovanni Marconi, MD, Elisabetta Todici, MD, PhD, Andrew A. Lane, MD, PhD, Evelyn Acuña-Cruz, MD, Eric DeConinck, MD, PhD, Eurica S. Wang, MD, Kendra Sweet, MD, David A Rizzieri, MD, Giovanni Marconi, MD, Luca Hazzarelli, MD, PhD,1
Daniel J. DeKlerk, MD, PhD,2 Pau Montesinos, PhD, MD, Federica Gigi, MD,3 Harry P. Erba, MD, PhD,4 Laura Koreps, MD, PhD,5 Hajo Kortmann, MD,6 Roland B. Walter, MD, PhD, MS,7 Ahmed Arbi, MD,8 Delphine Lebon9,10 Moshe Y. Levy, MD,11 Catilin M Sloss, PhD,12 Kara E Malcolm, RN,13 Patrick A Zwiderlick-McKay, MD, PhD,14 and Naval Dave, MD1

1MD Anderson Cancer Center, Houston, TX; 2Institute of Hematology "L. e A. Seràgnoli", Bologna, Italy; 3European Institute of Oncology RCs, Milan, Italy; 4Dana-Farber/Children's Cancer and Blood Disorders Ctr, Boston, MA; 5Hospital Universitari i Politècnic La Fe, Valencia, Spain; 6Inamurcancer University Hospital, Beaumont, France; 7Roswell Park Comprehensive Cancer Center, Buffalo, NY; 8Lee Oncology,勉強しなさい、勉強しなさい、勉強しなさい、勉強しなさい、勉強しなさい。; 9MD Anderson Cancer Center and Research Institute, Houston, TX; 10European Institute of Oncology, Milan, Italy; 11Duke University, Durham, NC; 12MD Anderson Cancer Center, Houston, TX; 13Fred Hutchinson Cancer Research Center, Seattle, WA; 14Dana-Farber Cancer Institute, Boston, MA; 15MD Anderson Cancer Center, Houston, TX; 16Baylor Charles A. Sammons Cancer Center, Dallas, TX; 17City of Hope, Duarte, CA; 18OncoSpectrum Charities A. Simons Cancer Center, Dallas, TX; 19ImmunoGen, Waltham, MA

©2021 ImmunoGen, Inc., Waltham MA, USA

Study Design and Trial Endpoints

Duration of composite complete response (DOCR) and Overall response rate (ORR) Efficacy was assessed using modified Severity Weighted Assessment Tool (mSWAT) for skin lesions, PET/CT, and blast proportion in bone marrow aspirates1

1CrC - CR (clinically) with minimal residual skin abnormality (cleared or almost clears all lesions from baseline; residual hyperpigmentation or abnormality with BPDCN identified by biopsy [no biopsy performed])

Summary

• IMGN632 in frontline BPDCN patients resulted in durable clinical complete responses
• IMGN632 can be administered as a breast outpatient infusion
• Favorable safety profile with no cases of ClS and limited grade ≥3 TEAEs
• Enrollment continues in the pivotal frontline and R/R cohorts (BPDCNtrials.com; NCT03386513)

References: